Former Novo CEO Lars Rebien appointed executive chair at Ferring
Lars Rebien Sørensen, the former long-standing CEO of Novo Nordisk, joined Ferring Pharmaceuticals as chair of the board in summer last year, and has now been appointed its executive chair, an amalgamation of a chief executive and chair position, although he retains most of his chair duties. The news comes with a record-breaking annual report from the company.
Chair of the Novo Nordisk Foundation, Lars Rebien Sørensen, has been appointed executive chair at pharmaceutical firm Ferring Pharmaceuticals | Photo: Finn Frandsen/Politiken/Ritzau Scanpix
by albert rønning-andersson, translated by daniel pedersen
The chair of the Novo Nordisk Foundation, Lars Rebien Sørensen, who stood at the helm of Novo Nordisk for many years, has been appointed Executive Chairman at Ferring Pharmaceuticals, a company press release has announced.
The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.
The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.
An analyst reacts to the news that GN’s chair is not seeking re-election this year – ”he has been key in helping GN secure a significant position on the hearing aid market.”
Microsoft is in the process of discontinuing Internet Explorer – and so are we. For a better experience, we recommend using one of the following browsers.